Citigroup’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-232,013
| Closed | -$789K | – | 7964 |
|
|
2018
Q3 | $789K | Buy |
232,013
+214,444
| +1,221% | +$773K | ﹤0.01% | 3763 |
|
|
2018
Q2 | $66K | Buy |
17,569
+14,410
| +456% | +$70.2K | ﹤0.01% | 6074 |
|
|
2018
Q1 | $13K | Buy |
3,159
+1,634
| +107% | +$7.61K | ﹤0.01% | 6957 |
|
|
2017
Q4 | $7K | Sell |
1,525
-39,207
| -96% | -$216K | ﹤0.01% | 7169 |
|
|
2017
Q3 | $290K | Buy |
40,732
+4,525
| +12% | +$32.5K | ﹤0.01% | 4658 |
|
|
2017
Q2 | $262K | Buy |
36,207
+16,989
| +88% | +$106K | ﹤0.01% | 4567 |
|
|
2017
Q1 | $118K | Sell |
19,218
-3,223
| -14% | -$17.7K | ﹤0.01% | 5083 |
|
|
2016
Q4 | $131K | Buy |
22,441
+491
| +2% | +$2.68K | ﹤0.01% | 5606 |
|
|
2016
Q3 | $117K | Sell |
21,950
-23,502
| -52% | -$127K | ﹤0.01% | 5099 |
|
|
2016
Q2 | $301K | Sell |
45,452
-51,041
| -53% | -$285K | ﹤0.01% | 4133 |
|
|
2016
Q1 | $451K | Buy |
96,493
+49,623
| +106% | +$198K | ﹤0.01% | 4241 |
|
|
2015
Q4 | $237K | Sell |
46,870
-70,139
| -60% | -$333K | ﹤0.01% | 4584 |
|
|
2015
Q3 | $412K | Buy |
117,009
+85,265
| +269% | +$571K | ﹤0.01% | 3932 |
|
|
2015
Q2 | $317K | Buy |
31,744
+5,772
| +22% | +$61.9K | ﹤0.01% | 4090 |
|
|
2015
Q1 | $331K | Buy |
25,972
+3,586
| +16% | +$46.1K | ﹤0.01% | 4107 |
|
|
2014
Q4 | $317K | Sell |
22,386
-799
| -3% | -$12.4K | ﹤0.01% | 4301 |
|
|
2014
Q3 | $319K | Buy |
23,185
+10,815
| +87% | +$166K | ﹤0.01% | 3882 |
|
|
2014
Q2 | $190K | Sell |
12,370
-15,687
| -56% | -$222K | ﹤0.01% | 4176 |
|
|
2014
Q1 | $477K | Sell |
28,057
-8,349
| -23% | -$126K | ﹤0.01% | 3520 |
|
|
2013
Q4 | $472K | Buy |
36,406
+29,791
| +450% | +$356K | ﹤0.01% | 3844 |
|
|
2013
Q3 | $67K | Sell |
6,615
-4,548
| -41% | -$40.5K | ﹤0.01% | 5056 |
|
|
2013
Q2 | $84K | Buy |
+11,163
| New | +$87.2K | ﹤0.01% | 5002 |
|
Citigroup's KERX Position: Q4 2018 in Review
Citigroup sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 232,013 shares — an estimated $789K sold.
Citigroup first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $789K in Q3 2018. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Citigroup reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Citigroup sold 232,013 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $789K.
- Citigroup first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Citigroup's Keryx Biopharmaceuticals Inc position peaked at $789K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Citigroup's 13F filing for Q4 2018, filed 12 Feb 2019.